Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments
Ann Acad Med Singap
.
2022 Dec;51(12):752-754.
doi: 10.47102/annals-acadmedsg.2022430.
Authors
Sylvia Chen
1
,
Wai Fook Leong
,
Sze Sing Lee
,
Balram Chowbay
Affiliation
1
Clinical Pharmacology Laboratory, Division of Cellular & Molecular Research, National Cancer Centre Singapore, Singapore.
PMID:
36592143
DOI:
10.47102/annals-acadmedsg.2022430
No abstract available
Publication types
Editorial
MeSH terms
Antiviral Agents / therapeutic use
Humans
Hydroxylamines
Pharmacogenetics*
Ritonavir* / therapeutic use
Substances
molnupiravir
nirmatrelvir
Ritonavir
Hydroxylamines
Antiviral Agents